Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 21;12(8):3023.
doi: 10.3390/jcm12083023.

The Inflammatory Bowel Disease-Disk Tool for Assessing Disability in Inflammatory Bowel Disease Patients: Validation of the Greek Version

Anastasia Katsoula  1 , Georgios Axiaris  2 , Afroditi Mpitouli  3 , Maria Palatianou  4 , Angeliki Christidou  5 , Nikolaos Dimitriadis  6 , Andreas Nakos  7 , Ploutarchos Pastras  8 , Panagiotis Kourkoulis  9 , Pantelis Karatzas  10 , Miltiadis Moutzoukis  11 , Charalampos Zlatinoudis  12 , Athanasios Philippidis  13 , Anastasia Kourikou  14 , Georgios Kokkotis  15 , Antonios Gklavas  16 , Angeliki Machaira  17 , Aikaterini Mantaka  18 , Persefoni Talimtzi  19 , Evaggelia Anagnostopoulou  18 , Ioannis E Koutroubakis  17 , Ioannis Papaconstantinou  16 , Georgios Bamias  15 , Spilios Manolakopoulos  14 , Nicoletta Mathou  20 , Konstantina Paraskeva  20 , Andreas Protopappas  13 , Eftychia Tsironi  12 , Konstantinos H Katsanos  11 , Dimitrios K Christodoulou  11 , Georgios Papatheodoridis  10 , Georgios Michalopoulos  9 , Georgios Theocharis  8 , Christos Triantos  8 , Ioannis Pachiadakis  7 , Konstantinos Soufleris  6 , Nikolaos Viazis  5 , Gerassimos J Mantzaris  5 , Georgios Tribonias  4 , Maria Tzouvala  4 , Angeliki Theodoropoulou  3 , Konstantinos Karmiris  3 , Evanthia Zampeli  2 , Spyridon Michopoulos  2 , Anna-Bettina Haidich  19 , Olga Giouleme  1
Affiliations

The Inflammatory Bowel Disease-Disk Tool for Assessing Disability in Inflammatory Bowel Disease Patients: Validation of the Greek Version

Anastasia Katsoula et al. J Clin Med. .

Abstract

Background: The Inflammatory Bowel Disease-Disk (IBD-Disk) is a physician-administered tool that evaluates the functional status of patients with Inflammatory Bowel Disease (IBD). The aim of our study was to validate the content of the IBD-Disk in a Greek cohort of IBD patients.

Methods: Two questionnaires [the IBD Disk and the IBD-Disability Index (IBD-DI)] were translated into Greek and administered to IBD patients at baseline visit, after 4 weeks and 6 months. Validation of the IBD Disk included measuring of concurrent validity, reproducibility, and internal consistency.

Results: A total of 300 patients were included at baseline and 269 at follow-up. There was a good correlation between the total scores of the IBD-Disk and IBD-DI at baseline (Pearson correlation 0.87, p < 0.001). Reproducibility of the total IBD-Disk score was very good [intra-class correlation coefficient (ICC), 95% confidence interval (CI) 0.89 (0.86-0.91)]. Cronbach's coefficient alpha for all items achieved 0.90 (95%CI 0.88-0.92), demonstrating a very good homogeneity of the IBD-Disk items. Female gender and extraintestinal manifestations were significantly associated with a higher IBD-Disk total score.

Conclusions: The Greek version of the IBD-Disk proved to be a reliable and valid tool in detecting and assessing IBD-related disability in a Greek cohort of IBD patients.

Keywords: Crohn’s disease; disability; inflammatory bowel disease-disk; ulcerative colitis; validation.

PubMed Disclaimer

Conflict of interest statement

Konstantinos Karmiris: speaker and/or consultant and/or advisory board member for: Abbvie, Aenorasis, Amgen, Ferring, Galenica, Genesis, Janssen, MSD, Pfizer, and Takeda. Ioannis E. Koutroubakis: Advisory board member for Abbvie, Astelas, Genesis, Janssen, MSD, Pharmacosmos, Pfizer, Shire, and Takeda; Speaker for AbbVie, Astelas, Genesis, Janssen, MSD, Takeda, and Mylan; research support Abbvie and Ferring. Spilios Manolakopoulos: Gilead Sciences: research grands, Abbvie research grands, Pfizer: advisory, celltrion: research grands, shire plc/ Takeda pharmaceutical: research grands. George Papatheodoridis: advisor/lecturer for Abbvie, Dicerna, Elpen, Gilead, GlaxoSmithKline, Ipsen, Janssen, Merck Sharp & Dohme, Roche, Spring Bank, Takeda; research grants Abbvie, Gilead; clinical trials: Abbvie, Astellas, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme, Noorik, Novartis, Novo Nordisk, Regulus, Roche, Takeda. Dimitrios K Christodoulou: advisor/lecturer for Abbvie, Janssen, Merck Sharp & Dohme, Takeda, Enorasis, Genesis, Pfizer, Ferring. Spyridon Michopoulos: Advisor or Lecturer for Pfizer, Takeda, Abbvie, Ferring, MSD, Janssen. Georgios Bamias: Advisor/lecturer for Janssen, Pfizer, Takeda, Abbvie, MSD, Mylan, Genesis Pharma, Adacyte Therapeutics, Amgen, Ferring, Cooper; Funding (Grants/Honoraria): Pfizer, Takeda, Abbvie, Aenorasis; Research/Clinical Trials: Abbvie. Konstantinos Soufleris: Advisory Board Member, Lecturer for Abbvie, Amgen, Genesis Pharma, Janssen, MSD, Mylan, Pfizer, Takeda. Funding/Research Support/Clinical Trials: Abbvie, Celgene, Faran, Ferring, Janssen, Roche, Shire, Takeda. Prof Giouleme Olga: is an advisory board member and has received speaker fees and research fees from Abbvie, MSD, Takeda, Janssen, Aenorasis, Pfizer, Ferring, Vianex, Genesis, Cross Pharmaceuticals, Amgen, Galenica. The rest of the authors confirm that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Correlation between the IBD-Disk total score and IBD-DI total score at baseline (n = 300).
Figure 2
Figure 2
Reliability of the IBD-Disk compared to the IBD-DI per item at baseline (n = 300).
Figure 2
Figure 2
Reliability of the IBD-Disk compared to the IBD-DI per item at baseline (n = 300).
See this image and copyright information in PMC

References

    1. Moradkhani A., Beckman L.J., Tabibian J.H. Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors. J. Crohn’s Col. 2013;7:467–473. doi: 10.1016/j.crohns.2012.07.012. - DOI - PubMed
    1. Shafer L.A., Walker J.R., Restall G., Chhibba T., Ivekovic M., Singh H., Targownik L.E., Bernstein C.N. Association Between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada. Inflamm. Bowel Dis. 2019;25:352–359. doi: 10.1093/ibd/izy236. - DOI - PubMed
    1. Marín L., Mañosa M., Garcia-Planella E., Gordillo J., Zabana Y., Cabré E., Domènech E. Sexual function and patients’ perceptions in inflammatory bowel disease: A case–control survey. J. Gastroenterol. 2013;48:713–720. doi: 10.1007/s00535-012-0700-2. - DOI - PubMed
    1. McDermott E., Mullen G., Moloney J., Keegan D., Byrne K., Doherty G.A., Cullen G., Malone K., Mulcahy H.E. Body Image Dissatisfaction: Clinical Features, and Psychosocial Disability in Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2015;21:353–360. doi: 10.1097/MIB.0000000000000287. - DOI - PubMed
    1. Gower-Rousseau C., Sarter H., Savoye G., Tavernier N., Fumery M., Sandborn W.J., Feagan B.G., Duhamel A., Guillon-Dellac N., Colombel J.F. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017;66:588–596. doi: 10.1136/gutjnl-2015-310151. - DOI - PubMed

LinkOut - more resources